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Abstract: 
Background: The safety and efficacy of targeted therapy in older patients (≥70 years) 
with metastatic colorectal cancer is not well evaluated. 
Patients and Materials: Outcomes of older patients (including overall survival (OS), 
progression-free survival (PFS), toxicity, and quality of life (QoL)) were compared to 
young patients using data from two large, previously reported, clinical trials—CO.17 
(cetuximab vs best supportive care) and CO.20 (cetuximab plus placebo vs cetuximab 
plus brivanib). Only patients with wildtype KRAS tumours were included. 
Results: 251/955 (26.3%) of patients were ≥70 years old. No significant differences in 
OS, PFS or grade 3/4 adverse events were observed between older and younger patients 
treated with cetuximab (or cetuximab with placebo) in either trial. Younger patients 
trended toward superior OS in both CO.17 (HR 1.80, p=0.16) and CO.20 (HR 1.34, 
p=0.07). QoL maintenance favoured younger patients in CO.17 (3.6 vs 5.7 months, 
p=0.046) but no difference of QoL maintenance was observed in the larger CO.20 trial 
(1.7 vs 1.8 months, p=0.64). Combination therapy of cetuximab and brivanib was 
significantly more toxic in older adults (87% vs 77%, p=0.03). 
Conclusions: OS, PFS, and toxicities were similar between older and younger patients 
with wild type KRAS metastatic colorectal cancer when treated with cetuximab. Both age 
groups likely experience similar QoL maintenance with cetuximab. Dual targeted therapy 
was significantly more toxic in older patients. 
Key Words: 
Elderly, metastatic colorectal cancer, cetuximab, survival, quality of life 
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MicroAbstract: 
Clinical trial data was used to evaluate cancer outcomes between older (n=251) and 
younger (n=704) patients with metastatic colorectal cancer who were treated with 
cetuximab. Overall survival trended towards favouring younger adults, but in general, 
outcomes, including quality of life benefit, were similar between age groups. 
 
Background: 
Colorectal cancer (CRC) is the third most prevalent type of cancer in North 
America, and is the second-leading cause of cancer-related death.1 The median age of 
diagnosis in the United States and other developed nations is 70 years old.2 The optimal 
treatment of older CRC patients is not well defined, as older patients have been 
underrepresented in clinical trials, resulting in a lapse of high-quality evidence.3-5 This 
patient population is unique in that treatment decisions are significantly influenced by co-
morbidities, risk aversion to treatment-related toxicities, and focus on maintenance of 
quality of life (QoL).6,7 
The past decade has experienced a large expansion in the number of treatment 
options for metastatic CRC. Various combinations of chemotherapy, including 
fluropyrimidines, irinotecan, and oxaliplatin have improved overall survival (OS) in CRC 
patients, and these combinations appear to have similar benefits and toxicities in both 
young and fit older patients.3,8-10 Numerous novel targeted therapies, including 
bevacizumab, cetuximab, panitumumab, aflibercept, ramucirumab, and regorafenib, have 
shown efficacy in CRC. Their use in older patients, as single agents or in combination 
with chemotherapy, is less well documented. The exception to this is bevacizumab, in 
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which several elderly-specific trials have been performed and are suggestive of efficacy 
and safety.11,12 
Cetuximab is a monoclonal antibody that inhibits the epithelial growth factor 
receptor (EGFR), resulting in inhibition of cell growth and apoptosis.13 Cetuximab 
significantly increases the OS and progression free survival (PFS) in metastatic CRC 
patients with wild-type RAS tumours.14-16 No immediate toxicity concerns have been 
identified in several previous studies evaluating older patients treated with cetuximab 
with or without chemotherapy.17-21 Fewer studies exist demonstrating the efficacy of 
cetuximab as a second-line or later agent in the elderly, and no studies have evaluated 
QoL in elderly patients treated with cetuximab.14,21 
This study was designed to compare the efficacy, safety, and QoL of older (70+ 
years) versus younger patients with chemorefractory metastatic CRC receiving targeted 
therapy using data from two previously reported clinical trials. 
Methods: 
Clinical Trials and Patient Populations 
This study analyzed CO.17 and CO.20, two previously reported phase III 
randomized controlled clinical trails conducted by the Canadian Cancer Trials Group 
(NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (NCT00079066 and 
NCT00640471, respectively).14,22 In the CO.17 trial, 572 patients were randomized to 
receive either best supportive care (BSC) or BSC with cetuximab. Cetuximab 
demonstrated superior OS, PFS, and longer preserved QoL, as compared to BSC.14 
Subsequent studies found this benefit was limited to patients with wild-type RAS 
tumours.14-16 
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CO.20 randomized 750 patients to cetuximab plus placebo or to cetuximab plus 
brivanib alaninate, a dual inhibitor of vascular endothelial growth factor (VEGF) and 
fibroblast growth factor receptor (FGFR). The CO.20 trial demonstrated that adding 
brivanib to cetuximab resulted in improved PFS but no difference in OS and an earlier 
deterioration in QOL.22 
Eligibility criteria were similar between trials, and included the presence of 
advanced colorectal cancer, no response or intolerable to treatment with 
fluoropyrimidine, irinotecan, and oxaliplatin therapy, ECOG 0-2, and adequate bone 
marrow, renal, and hepatic function.  
In this study, only patients with wild-type KRAS tumours were included; patient 
inclusion/exclusions for CO.17/20 are demonstrated in CONSORTlike diagrams in 
Figure 1 and Figure 2, respectively. Older patients were defined as those ≥70 years, 
consistent with a notion from the International Society of Geriatric Oncology stating “70 
years is currently the most commonly used cut-off for defining patients as elderly”.  
Outcome Measures 
OS and PFS were measured from time of randomization. Severe toxicity was measured 
using the incidence of grade 2 and grade 3/4 adverse events using the National Cancer 
Institute Common Toxicity Criteria versions 2.0 (for CO.17) and 3.0 (for CO.20). QoL 
was measured the European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire C30 (EORTC QLQ-C30) in each trial. All outcome measures are 
calculated and reported with similar methodology as the original CO.17 and CO.20 
trials.14,22  
Statistical Analysis 
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OS and PFS were compared between age groups using multivariate Cox models adjusting 
for potential prognostic factors included in the primary analyses of the trials. Specifically, 
the following baseline covariates were included in multivariate Cox models for CO.17: 
gender (male vs. female), ECOG performance status (2 vs. 0 and 1 vs. 0), body mass 
index (between 20 and 25 vs. less than 20 and higher than 25 vs. less than 20), site of 
primary (rectum only vs. colon only, and both rectum and colon vs. colon only), time 
from diagnosis to randomization (less than 2 years vs. 2 years or longer), baseline LDH 
level (above upper limit of normal (ULN) vs. equal to or less than ULN), alkaline 
phosphatase level (above ULN vs. equal to or less than ULN), anemia (grade 1 or higher 
vs. 0), serum creatinine (grade 1 or higher vs. 0), number of previous chemotherapy drug 
classes (more than 2 vs. 2 or less), side of primary tumor (right vs. left), Charlson co-
morbidity score (0 vs. 1 or higher), and polypharmacy (five or more concurrent 
medications vs. four or less). 23,24 Cox models for CO.20 results included ECOG 
performance status, gender, baseline LDH level, alkaline phosphatase level, anemia, 
number of organ sites (2 or less vs. more than 2), number of chemotherapy classes 
received, previous VEGFR treatment (yes vs. no), liver metastases (yes vs. no), side of 
primary tumor, Charlson co-morbidity score, and polypharmacy.  
 A Charlson co-morbidity score was calculated after reviewing patient co-
morbidities captured by the clinical trial intake screening forms; ICD codes were not 
available for classification.  
Safety profiles were compared by Fisher’s exact test between two age groups. 
QoL was measured with the EORTC QLQ-C30, using time to deterioration by ≥10 points 
of global health status as an endpoint.  
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Results: 
Patient Characteristics 
A total of 955 patients were included in the analysis of this study, of which 251 (26.3%) 
were 70 years or older at time of enrollment.  In CO.17, 58/230 (25.3%) were aged 70 or 
older, while in CO. 20, 193/725 (26.6%) patients were over the age of 70.  Baseline 
characteristics of patients in each trial are listed in Tables 1. In CO.17, baseline serum 
creatinine, presence of co-morbidities, and treatment arm were associated with age in 
univariate and multivariate analysis, while in CO.20, only liver metastases and presence 
of co-morbidities were associated with age in both univariate and multivariate analyses. 
Overall Survival and Progression Free Survival 
OS and PFS were statistically similar between older and younger patients treated with 
cetuximab in both CO.17 and CO.20. (Table 2) For cetuximab treated patients in CO.17, 
the median OS was 8.0 vs 9.7 months (HR 1.80, p=0.16) and the median PFS was 3.5 vs 
3.8 months (HR 1.23, p=0.56) for older and younger patients, respectively. For cetuximab 
(plus placebo) treated patients in CO.20, the median OS was 8.3 vs 9.5 months (HR 1.34, 
p=0.07) and the median PFS was 2.8 vs 3.5 months (HR 1.25, p=0.16) for older and 
younger patients, respectively. 
 In CO.17, only younger patients treated with cetuximab had a significant 
improvement in both OS and PFS as compared to those receiving BSC (OS= 9.7 vs 4.8 
months, p= 0.0006 and PFS= 3.8 vs 1.8 months, p<0.0001, for cetuximab vs BSC 
respectively). (Table 3) The OS and PFS did not reach statistical significance for older 
patients treated with cetuximab vs those receiving BSC. (Table 3) 
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 Finally, in CO.20, both older and younger patients treated with cetuximab and 
brivanib had statistically similar OS (7.6 vs 9.1 months, respectively, p=0.62) and PFS 
(3.7 vs 5.3 months, respectively, p=0.16). (Table 4) 
Toxicity and Quality of Life 
Grade 3/4 adverse event rates are listed for CO.17 and CO.20 in tables 5 and 6, 
respectively. Older and younger patients receiving cetuximab experienced similar rates of 
grade 3/4 adverse rates in both CO.17 (81% vs 78%, p=0.71) and CO.20 (63% vs 52%, 
p=0.09). (Table 2). In CO.20, older patients treated with cetuximab experienced higher 
incidences of grade 3/4 abdominal pain (11% vs 4%, p=0.01), dehydration (4% vs 1%, 
p=0.04), and confusion (3% vs 0%, p=0.01) than younger patients. (Table 6) Rates of 
grade 3/4 adverse events were higher in patients treated with cetuximab as compared to 
those receiving BSC, but this was only significant in younger patients. (Table 3)  
 Grade 2 adverse events for CO.17 and CO.20 are listed in Supplemental 
Table 1. All patients treated with cetuximab in CO.17 experienced grade 2 adverse 
events, although grade 2 events were frequent in the BSC arm (93% in younger patients, 
81% in older patients). Similarly, 95% of older and younger patients in CO.20 
experienced grade 2 adverse events when treated with cetuximab and placebo. There 
were no significant differences between age groups for specific symptoms. The 
combination of cetuximab and brivanib was significantly more toxic in older patients 
(87%) than younger patients (77%, p=0.03). (Table 4 and 6) Grade 3/4 fatigue was the 
most common side effect more often seen in older patients (38% vs 22%, p=0.002, Table 
6). 
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 In patients treated with cetuximab (or cetuximab with placebo), QoL outcomes 
varied by trial. In CO.17, older patients treated with cetuximab had a less robust benefit 
to QoL as compared to younger patients (3.6 vs 5.7 months, p=0.046), whereas in the 
larger CO.20 trial, QoL maintenance was similar between older and young (1.8 vs 1.6 
months, p=0.64, respectively). (Table 2) 
 When comparing cetuximab to BSC, neither older nor young patients had a 
statistically significant improvement in QoL with cetuximab treatment. (Table 3) In 
CO.20, the combination of cetuximab and brivanib resulted in a maintenance of QoL of 
0.9 months for older patients vs 1.2 months for younger patients (p=0.02). (Table 4)  
Discussion: 
This study was designed to evaluate the outcomes of older patients with KRAS 
wild-type metastatic CRC undergoing targeted therapy. Our re-analysis of CO.17 and 
CO.20 suggest that both older and younger patients treated with cetuximab have 
statistically similar OS, PFS, and QoL maintenance, while experiencing similar rates of 
serious adverse events. However, this unplanned sub-analysis (and therefore 
underpowered) does trend towards improved OS for younger patients in both CO.17 (HR 
1.80, p=0.16) and CO.20 (HR 1.34, p=0.07). 
Several previous studies examining the outcomes of older patients treated with 
cetuximab have concluded there are no differences in outcomes between young and older 
patients. The original CO.17 trial included a planned sub-analysis of patients <65 and ≥ 
65 years old, from which no differences were observed for OS, PFS, or overall response 
rates.14 A subsequent analysis found no relationship between age (using a cutoff of <65), 
co-morbidities (measured by Charlson co-morbidity index), and OS.19 In heavily pre-
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treated patients, an observational study of 305 older patients (≥65 years old) saw no 
difference in adverse events or PFS as compared to younger patients.20 A pooled analysis 
of the OPUS and CRYSTAL trials concluded that first-line cetuximab with chemotherapy 
was equally effective and had similar toxicities for older (≥70) and younger patients.17 
 The primary difference between our analysis and previous analyses of CO.17 is 
the higher age cutoff of ≥70, as this age is more consistent with current trends in geriatric 
oncology, and the complete exclusion of patients with mutant KRAS. This study also 
differs from other reports in that it uses phase III clinical trial data, includes only KRAS 
wildtype patients, and reports on all of OS, PFS, toxicity, and QoL. Additionally, the 
majority of other studies thus far have examined cetuximab in combination with 
chemotherapy. These differences may explain why our analysis showed a strong trend 
towards younger patients having more prolonged OS.  
While OS and PFS outcomes are important, treatment toxicity and QoL 
maintenance are often more heavily weighted in treatment decisions for older patients.25 
To date, this is the first analysis to compare QoL outcomes between older and younger 
patients treated with cetuximab. Maintenance of QoL was significantly shorter in older 
patients than younger patients in the CO.17 trial; however, in the larger CO.20 trial the 
maintenance of QoL was similar between age groups. The reason for this discrepancy is 
not abundantly clear, as both trials followed similar protocols with the same QoL survey. 
This may be due to a type II error, as the older CO.17 QoL data included 17 patients 
whereas the CO.20 data included 84 patients. 
Toxicity results from CO.17 intuitively demonstrate that cetuximab treatment is 
more toxic than BSC alone, and both trials show that cetuximab-related grade 2 and 3/4 
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toxicities are similar between age groups. Overall, treatment with cetuximab was 
associated with a 100% incidence of grade 2 adverse events but this must be contrasted 
against the fact that >80% of patients receiving BSC will also develop grade 2 adverse 
events. This shows that both treatment and non-treatment will be associated with 
burdensome symptoms. 
Combination treatment with cetuximab and brivanib was significantly more toxic 
in older patients than younger patients. Various combinations of targeted therapies have 
been trialed in metastatic CRC, but thus far none have been approved. In the original 
CO.20 trial, the combination of cetuximab plus brivanib was found to be more toxic than 
cetuximab with placebo, and combination therapy did not prolong OS.22 Several phase I 
and phase II studies have combined targeted therapies, including VEGF and EGFR 
inhibitors, with and without cytotoxic agents, and thus far the combinations appear to be 
reasonably tolerated, with predictable toxicities.26-29 Unfortunately, the median age in 
these trials was <65 and the vast majority of patients had an ECOG status of 0-1, making 
it difficult to generalize these results. Nonetheless, our data suggest that greater baseline 
toxicities of these combinations may adversely impact older patients to a greater extent 
than in younger patients. 
Fifty six percent of patients diagnosed with CRC are over the age of 65, yet the 
number of older adults enrolled in clinical trials remains disproportionately low; this will 
inevitably further cloud the optimal treatment of this patient group.30 In this study, only 
26.3% of patients were over the age of 70. As an example of up-and-coming therapies, 
the phase II trial of trastuzumab and lapatinib in treatment refractory metastatic colorectal 
cancer included only patients with an ECOG of 0-1 and no patients were over the age of 
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70.31 For immune checkpoint therapy trials, including CheckMate 142 (nivolumab vs 
nivolumab with ipilimumab; NCT02060188) and KEYNOTE 177 (pembrolizumab vs 
investigator’s choice; NCT02563002), it is not yet clear what proportion of patients will 
be older.  
Future studies dedicated to the geriatric population that incorporate geriatric 
assessments are still needed. Several recent commentaries by the American Society of 
Clinical Oncology, Friends of Cancer Research, and the US Food and Drug 
Administration have published calls for the broadening of clinical trial eligibility criteria 
to be more representative of the general population.32,33 Specifically, these groups 
advocate for inclusion of patients with clinically stable brain metastases, HIV-infected 
patients, patients with prior or concurrent malignancies, and a liberalization of renal 
function restrictions.32 Lichtman et al. (2017) also suggest improved assessment of 
functional status to better stratify fit versus frail patients in clinical trial patietns.33 The 
ASCO Guideline for Geriatric Oncology recommends inclusion of the geriatric 
assessment for patients >65 years old in clinical trials.34 This tool includes an evaluation 
of functional status (activities of daily living, mobility), physical performance, 
comorbidities, depression, social support, nutritional status, and cognitive status.35 
Development and incorporation into trials will likely allow for more informed decision 
making when selecting treatments for older patients. 
This study is limited by the fact that older patients in clinical trials rarely reflect 
the “true” older population, who may have more comorbidities and worse performance 
statuses. While our results are not generalizable to frail elderly patients, 20% of older 
patients in CO.17 had an ECOG of 2 and older patients were more likely to have multiple 
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comorbidities. Similarly, in CO.20 the older cohort had significantly more comorbidities, 
suggesting our older cohort was unique from the younger cohort. The calculation of 
Charlson co-morbidity index is limited by the lack of ICD-10 codes; there was also no 
manner to determine or adjust for the severity of each co-morbidity. Unfortunately, our 
limited sample size prevented a subset analysis by comorbidities or presence of 
polypharmacy. A sensitivity analysis of age was not feasible given the limited number of 
older patients >75; sample size also limited the usefulness of analyzing age as a 
continuous variable. 
 CO.17 and CO.20 were not originally designed to measure geriatric outcomes 
and as such no comprehensive geriatric assessments were performed, however, this is the 
first study to report QoL outcomes in older patients treated with cetuximab. Other 
limitations include the retrospective nature of this study, which was conducted using data 
from well-designed clinical trials, and only controlling for wild-type KRAS rather than 
extended RAS. Finally, it is important to recognize that age alone should not be used to 
dictate treatment, and that physiological age may vastly differ from chronological age.   
Conclusions: 
Age was not associated with statistically superior OS or PFS in patients with 
chemorefractory, KRAS wildtype metastatic CRC treated with cetuximab. However, a 
strong trend towards improved OS for younger patients treated with cetuximab was 
observed in both trials. Older patients likely experience similar QoL maintenance and 
similar toxicity rates as compared to younger patients, however, adverse event rates are 
high. The decision to initiate targeted therapy in older patients should balance modest 
improvements in cancer-specific outcomes with high incidence of toxicity. Dual targeted 
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therapy with cetuximab and brivanib was significantly more toxic in the older population. 
Further recruitment of older patients into clinical trials and elder-specific trials are 
necessary to better guide treatment decisions in this population. 
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Table 1:  Baseline Patient, Disease and Treatment Characteristics by Age in CO.17 and CO.20 Patients with Wild-type 
Kras 
 
 CO. 17 CO.20 
Characteristic Age<70 
(N=172) 
Age>=70 
(N=58) 
P-value* 
(Univari
ate) 
P-
value** 
(Multiva
riate) 
Age<70 
(N=532) 
Age>=70 
(N=193) 
P-value* 
(Univari
ate) 
P-
value** 
(Multiva
riate) 
Gender   0.75    0.11  
     Female 54  (31.4) 20  (34.5)   198  (37.2) 59  (30.6)   
     Male 118  (68.6) 38  (65.5)   334  (62.8) 134 (69.4)   
ECOG performance 
status      
  0.13    0.67  
     0-1 136  (79.0) 47  (81.0)   482 (90.6) 173 (89.6)   
     2 36  (21.0) 11  (19.0)   50 (9.4) 20 (10.4)   
BMI (kg/m2)   0.44      
    <20 14  (8.1) 3  (5.2)   -- --   
    20-25 50  (29.1) 22  (37.9)   -- --   
    >25 108  (62.8) 33  (56.9)   -- --   
Site of primary   0.83      
     Colon only 104  (60.4) 33  (56.9)   -- --   
     Rectum Only 32  (18.6) 11  (19.0)   -- --   
     Colon and Rectum 36  (20.9) 14  (24.1)   -- --   
Number of metastatic 
organ sites 
 
  
 
  0.22 
 
     ≤ 2 -- --   423 (79.5) 145  (75.1)   
      >2 -- --   109  (20.5) 48  (24.9)   
Presence of liver 
metastases 
      0.003 0.004 
     Yes -- --   365  (68.6) 154  (79.8)   
     No -- --   167  (31.4) 39  (20.2)   
Prior VEGFR target 
therapy 
      0.35  
     Yes -- --   229  (43.0) 75  (38.9)   
     No -- --   303  (57.0) 118  (61.1)   
Time from initial 
diagnosis to 
randomization (year) 
 
 0.29 
 
 
    
     >=2 years 91  (52.9) 36  (62.1)   -- --   
     < 2 years 81  (47.1) 22  (37.9)   -- --   
LDH   0.30    0.85  
     ≤UNL 47  (29.4) 12  (21.4)   157  (29.5) 54  (28.0)   
     >UNL 113  (70.6) 44  (78.6)   356  (66.9) 128  (66.3)   
Alkaline phosphatase   1.00    0.60  
     ≤UNL 47  (27.5) 16  (27.6)   192  (36.1) 74  (38.3)   
     >UNL 124  (72.5) 42  (72.4)   335  (63.0) 117  (60.6)   
Hemoglobin   0.34 0.21   0.10 0.43 
     CTC grade 0 60  (34.9) 16  (27.6)   210  (39.5) 63  (32.6)   
     CTC grade≥1 112  (65.1) 42  (72.4)   335  (60.5) 130  (67.4)   
Serum Creatinine   0.003 0.002     
     CTC grade 0 163  (94.8) 47  (81.0)       
     CTC grade≥1 9  (5.2) 11  (19.0)       
Number of previous 
chemo drug classes 
   
0.22 
 
0.11 
   
1.00 
 
     ≤ 2 9  (5.2) 6  (10.3)   21  (3.9) 7  (3.6)   
      >2 163  (94.8) 52  (89.7)   511  (96.1) 186  (96.4)   
 Prior thymidylate 
synthase inhibitor 
  1.0    0.57  
   Yes 172 (100) 58 (100)   529 (99.4) 193 (100)   
   No 0 (0) 0 (0)   3 (0.6) 0 (0)   
Prior irnotecan    0.15    0.80  
   Yes 166 (96.5) 53 (91.4)   518 (97.4) 187 (96.9)   
   No 6 (3.5) 5 (8.6)   14 (2.6) 6 (3.1)   
Prior oxaliplatin   0.21    0.69  
   Yes 168 (97.7) 54 (93.1)   525 (98.7) 192 (99.5)   
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   No 4 (2.3) 4 (6.9)   7 (1.3) 1 (0.5)   
Co-morbidity score        0.006 0.005   <0.001 <0.0001 
      0 134  (77.9) 34  (58.6)   449  (84.4) 134  (69.4)   
     1 38  (22.1) 24  (41.4)   83  (15.6) 59  (30.6)   
Number of 
concomitant 
medications 
  
0.35 
   0.06 0.43 
     <5 108  (62.8) 32  (55.2)   302  (56.8) 94  (48.7)   
     ≥5 64  (37.2) 26  (44.8)   230  (43.2) 99  (51.3)   
Side of primary tumor   0.70    0.67  
     Left 80  (46.5) 25  (43.1)   227  (42.7) 91  (47.2)   
      Right 41 (23.8) 15  (25.9)   110  (20.7) 49  (25.4)   
Treatment   0.006 0.008   0.45  
     BSC only 75  (43.6) 38  (65.5)   -- --   
     Cetuximab + BSC 97  (56.4) 20  (34.5)      --           --   
    Brivanib + Cetuximab -- --   263  (49.4) 102  (52.8)   
     Placebo + Cetuximab -- --   269  (50.6) 91  (47.2)   
* From Wilcoxon test for continuous variables and Fisher’s exact test for categorical variables 
** From logistic regression model including characteristics with p<0.1 in univariate analysis as covariates. 
BMI= body mass index, LDH= lactate dehydrogenase, VEGFR= vascular endothelial growth factor receptor, 
 UNL= upper limit of normal, CTC= common terminology criteria, BSC= best supportive care, --= data not available/applicable 
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Table 2. Cancer specific outcomes of older (≥70 years) and younger patients treated with cetuximab 
(in CO.17) or cetuximab with placebo (in CO.20). 
 
CO.17 Outcomes N Older (95% 
CI) 
N Younger 
(95% CI) 
Hazard Ratio (95% CI) P-Value 
OS (months) 
PFS (months) 
Grade 3/4 Toxicity 
QoL (months until 
deterioration) 
20 
20 
53 
17 
8.0 (5.7-10.3) 
3.5 (1.8-5.4) 
81% 
3.6 (1.0-NA) 
97 
97 
235 
88 
9.7 (7.2-10.6) 
3.8 (3.0-5.4) 
78% 
5.7 (5.7-5.7) 
 
1.80 (0.80-4.09) 
1.23 (0.93-2.84) 
n/a 
n/a 
 
0.16 
0.56 
0.71 
0.046 
CO.20 Outcomes N Older (95% 
CI) 
N Younger 
(95% CI) 
Hazard Ratio (95% CI) P-Value 
OS (months) 
PFS (months) 
Grade 3/4 Toxicity 
QoL (months until 
deterioration) 
94 
94 
94 
84 
7.6 (5.6-9.2) 
2.8 (1.8-3.7) 
63% 
1.8 (1.2-2.8) 
 
280 
280 
280 
264 
9.1 (8.5-11.4) 
3.5 (3.3-3.6) 
52% 
1.6 (1.2-2.0) 
1.34 (0.98-1.83) 
1.25 (0.92-1.70) 
n/a 
n/a 
0.07 
0.16 
0.09 
0.64 
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Table 3. Comparisons of cancer specific outcomes between patients treated with cetuximab or best 
supportive care in CO.17, stratified by age. 
CO.17 Older  N Cetuximab + 
BSC (95% CI) 
N BSC Alone (95% 
CI) 
Hazard Ratio (95% 
CI) 
P-Value 
OS (months) 
PFS (months) 
Grade 3/4 Toxicity 
QoL (months until 
deterioration) 
20 
20 
53 
17 
 
 
8.0 (5.7-10.3) 
3.5 (1.8-5.4) 
76% 
3.6 (1.0-NA) 
38 
38 
80 
31 
5.1 (2.7-8.3) 
2.3 (1.8-3.3) 
51% 
2.3 (1.81-NA) 
0.60 (0.32-1.14) 
0.67 (0.38-1.19) 
n/a 
n/a 
0.11 
0.17 
0.09 
0.94 
CO.17 Young N Cetuximab + 
BSC (95% CI) 
N BSC Alone (95% 
CI) 
Hazard Ratio P-Value 
OS (months) 
PFS (months) 
Grade 3/4 Toxicity 
QoL (months until 
deterioration) 
97 
97 
235 
88 
 
9.7 (7.2-10.6) 
3.8 (3.0-5.4) 
78% 
5.7 (5.7-5.7) 
75 
75 
194 
51 
4.8 (4.1-5.4) 
1.8 (1.7-1.9) 
62% 
3.7 (2.4-4.0) 
0.55 (0.39-0.78) 
0.31 (0.22-0.44) 
n/a 
n/a 
0.0006 
<0.0001 
0.03 
0.06 
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Table 4. Comparison of cancer specific outcomes between older and younger patients treated with 
brivanib and cetuximab in CO.20. 
 
CO.20 Brivanib 
plus Cetuximab 
Outcomes 
N Older (95% 
CI) 
N Younger (95% 
CI) 
Hazard Ratio (95% 
CI) 
P-Value 
OS (months) 
PFS (months) 
Grade 3/4 Toxicity 
QoL (months until 
deterioration) 
105 
105 
105 
87 
7.6 (5.2-8.8) 
3.7 (3.3-5.4) 
87% 
0.9 (0.6-1.2) 
271 
271 
271 
244 
9.1 (8.0-10.1) 
5.3 (4.0-5.5) 
77% 
1.2 (1.0-1.7) 
1.08 (0.78-1.50) 
1.25 (0.92-1.70) 
n/a 
n/a 
0.62 
0.16 
0.03 
0.02 
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Table 5: Number of Patients with Toxicities (Grade 3 or higher) in CO.17 
 
Toxicity 
Cetuximab + BSC BSC 
Age < 70 ≥ Age 70 
P 
Age < 70 ≥ Age 70 
P 
Number pts 96 21 73 37 
Any  75 (78) 16 (76) 1.0 45 (62) 19 (51) 0.31 
Edema 4 (4) 2 (10) 0.59 6 (8) 3 (8) 1.0 
Fatigue 29 (30) 6 (29) 1.0 18 (25) 9 (24) 1.0 
Anorexia 5 (5) 3 (14) 0.15 2 (3) 1 (3) 1.0 
Constipation 2 (2) 2 (10) 0.15 2 (3) 1 (3) 1.0 
Nausea 6 (6) 0 (0) 0.37 6 (8) 1 (3) 0.42 
Vomiting 6 (6) 0 (0) 0.37 4 (6) 0 (0) 0.30 
Infection w/o 
neutropenia 
8 (8) 2 (10) 1.0 5 (7) 0 (0) 0.17 
Confusion 5 (5) 3 (14) 0.15 1 (1) 0 (0) 1.0 
Abdominal 
pain 
14 (15) 2 (10) 0.73 12 (16) 2 (5) 0.13 
Other pain 17 (18) 2 (10) 0.52 6 (8) 1 (3) 0.42 
Dyspnea 16 (17) 3 (14) 1.0 12 (16) 4 (11) 0.57 
Rash 18 (19) 3 (14) 0.76 0 (0) 1 (3) 0.34 
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Table 6: Number of Patients with Toxicities (Grade 3 or higher) in CO.20 
Toxicity 
Cetuximab + Brivanib   Cetuximab + Placebo  
Age<70 ≥ Age 70 
P 
Age<70 ≥ Age 70 
P 
Number pts 263 102 269 91 
Any  203 (77) 89 (87) 0.02 139 (52) 57 (63) 0.09 
Fatigue 57 (22)  39 (38) 0.001 27 (10) 13 (14) 0.33 
Hypertension 25 (10)  13 (13) 0.34 2 (1)  2 (2) 0.57 
Rash 23 (9) 13 (13) 0.24 16 (6) 4 (4) 0.62 
Abdominal 
pain 
29 (11) 8 (8) 0.44 9 (3) 10 (11) 0.008 
Dyspnea 22 (8) 13 (13) 0.23 15 (6) 5 (5) 1.0 
Diarrhea 21 (8) 6 (6) 0.52 7 (3) 4 (4) 0.48 
Dehydration 15 (6) 10 (10) 0.17 2 (1) 4 (4) 0.04 
Confusion 6 (2) 9 (9) 0.008 0 (0) 3 (3) 0.01 
Anorexia 10 (4) 8 (8) 0.17 4 (1) 1 (1) 1.0 
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CO.17 Patient Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow diagram demonstrating the selection of patients from the original CO.20 trial and the 
division amongst age and treatment groups. 
 
Patients Randomized in 
Original Analysis (N=572) 
Excluded for mutant KRAS (N=342) 
Patients >= 70 (N=58) 
Randomized (N=230) 
BSC Only (N=38) 
Patients < 70 (N=172) 
Cetuximab + BSC 
(N= 97) 
BSC Only (N=75) Cetuximab + BSC 
(N=20) 
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CO.20 Patient Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Flow diagram demonstrating the selection of patients from the original CO.20 trial and the 
division amongst age and treatment groups. 
 
Patients Randomized in 
Original Analysis (N=750) 
Excluded for non-wildtype KRAS (N=25) 
Patients >= 70 (N=193) 
Randomized (N=725) 
Cetuximab + 
Placebo (N=91) 
Patients < 70 (N=532) 
Cetuximab + 
Brivanib (N= 263) 
Cetuximab + 
Placebo (N=269) 
Cetuximab + 
Brivanib (N=102) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplemental Table 1: Number of Patients with Toxicities (Grade 2 or higher) 
 
(1) CO.17 Treated Patients with Wild-type Kras 
 
 
Toxicity 
Cetuximab + BSC BSC 
Age < 70 ≥ Age 70 
p 
Age < 70 ≥ Age 70 
p 
Number pts 96 21 73 37 
Any 95 (99) 21 (100) 1.0 68 (93) 30 (81) 0.10 
Edema 17 (18) 3 (14) 0.77 15 (21) 8 (22) 1.0 
Fatigue 55 (57) 15 (71) 0.33 46 (63) 19 (51) 0.31 
Anorexia 27 (26) 6 (29) 1.0 30 (41) 11 (30) 0.30 
Constipation 22 (23) 9 (43) 0.10 13 (18) 6 (16) 1.0 
Nausea 22 (23) 2 (10) 0.24 17 (23) 6 (16) 0.46 
Vomiting 20 (21) 2 (10) 0.36 12 (16) 2 (5) 0.13 
Infection w/o 
neutropenia 
24 (25) 5 (24) 1.0 10 (14) 5 (14) 1.0 
Confusion 9 (9) 5 (24) 0.13 2 (3) 0 (0) 0.55 
Abdominal pain 38 (40) 9 (43) 0.81 26 (36) 12 (32) 0.83 
Other pain 34 (35) 8 (38) 1.0 17 (23) 5 (14) 0.31 
Dyspnea 46 (48) 10 (48) 1.0 31 (43) 18 (49) 0.55 
Rash 58 (60) 10 (48) 0.33 3 (4) 2 (5) 1.0 
 
(2) CO.20 Treated Patients with Wild-type Kras 
 
Toxicity 
Brivanib + Cetuximab Placebo + Cetuximab 
Age<70 ≥ Age 70 
P 
Age<70 ≥ Age 70 
P 
Number pts 263 102 269 91 
Any 262 (100) 101 (99) 1.0 255 (95) 86 (95) 1.0 
Fatigue 160 (61) 71 (70) 0.18 103 (38) 40 (44) 0.39 
Hypertension 59 (22) 30 (29) 0.22 13 (5) 6 (7) 0.59 
Rash 116 (44) 48 (47) 0.73 111 (41) 27 (30) 0.06 
Abdominal pain 73 (28) 22 (22) 0.23 53 (20) 25 (27) 0.14 
Dyspnea 45 (17) 25 (25) 0.14 26 (10) 15 (16) 0.09 
Diarrhea 81 (31) 30 (29) 0.80 26 (10) 16 (18) 0.06 
Dehydration 26 (10) 18 (18) 0.05 6 (2) 5 (5) 0.15 
Confusion 10 (4) 13 (13) 0.003 4 (1) 3 (3) 0.37 
Anorexia 77 (29) 28 (27) 0.70 44 (16) 17 (19) 0.63 
 
